In­tel­lia plans to file IND for AATD tri­al next year; As­cid­i­an rais­es $40M

In­tel­lia aims to start AATD tri­al next year: The gene edit­ing com­pa­ny an­nounced Thurs­day that it plans to file an ap­pli­ca­tion to start clin­i­cal tri­als for an al­pha-1 an­tit­rypsin de­fi­cien­cy (AATD) lung dis­ease pro­gram in the first quar­ter of next year. This would be In­tel­lia’s third pro­gram to reach hu­man tri­als. Un­like its cur­rent two pro­grams, which knock out dis­ease-caus­ing genes, the AATD ther­a­py would in­volve in­sert­ing a healthy copy of a gene en­cod­ing al­pha-1 an­tit­rypsin pro­tein. In­tel­lia did not spec­i­fy whether it plans to be­gin tri­als for NT­LA-3001 in the US or abroad. The biotech al­so said it stopped work on NT­LA-2003, its oth­er pre­clin­i­cal AATD gene edit­ing treat­ment, which was meant for the liv­er as op­posed to lung dis­ease. NT­LA-2003 was meant to knock out the gene pro­duc­ing ab­nor­mal pro­teins in the liv­er. — Lei Lei Wu

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER